LDX Share Price Performance
AU$0.084
0.04 (104.88%)
Price AU$0.084
Share PriceAU$0.084
LDX Community Narratives
There are no narratives available yet.
Recent LDX News & Updates
No updates
Lumos Diagnostics Holdings Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0067
- Gross Margin
- 63.25%
- Net Profit Margin
- -33.97%
- Debt/Equity Ratio
- 0%
Lumos Diagnostics Holdings Limited Competitors
About LDX
- Founded
- 2018
- Employees
- n/a
- CEO
- WebsiteView website
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers. The company was incorporated in 2018 and is based in Carlsbad, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading